ring finger protein 113BGenealiases: RNF161 · ZNF183L1 · bA10G5.1
Q-omics provides the consensus-scored RNF113B profile across patient tissues and cancer cell-line models. RNF113B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF113B is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RNF113B protein abundance shows 14,729 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, BRCA, and PDAC as cancer lineages where RNF113B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF113B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF113B survival associations across molecular data types. RNF113B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF113B RNA expression–survival associations across cancer types. High RNF113B expression shows unfavorable associations in ACC, DLBC, THCA and SKCM, but favorable associations in BRCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNF113B RNA expression.
This table summarizes RNF113B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF113B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF113B shows higher tumor expression in BRCA, PRAD, STAD, READ and COAD. The BRCA box plot shows higher RNF113B RNA expression in tumor versus normal tissue (log2 FC = +0.151, t-test p = .023).
This table shows molecular features associated with RNF113B in patient tissues and cancer cell lines. In patient samples, RNF113B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF113B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
